RCS - OptiBiotix Health - Commercial Appointments

OptiBiotix HealthAnnouncement

01/03/2022 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220301:nRSA0988Da&default-theme=true

RNS Number : 0988D  OptiBiotix Health PLC  01 March 2022

OptiBiotix Health plc

("OptiBiotix" or the "Company")

 

Commercial Appointments

 

OptiBiotix Health plc (AIM:
OPTI), a life sciences business developing compounds to tackle obesity, high
cholesterol, blood pressure, diabetes, announces the following
appointments(1): Zac Sniderman as Business Development & Sales Director
North America, Shiraz Butt as E-Commerce Director and Karl Burkitt as
Marketing Director.

 

Zac brings a broad experience developing a food and supplement ingredient
businesses in North America working for Galenicum Speciality Ingredients,
Jarrow Formulas and Best Ground International. He has an entrepreneurial
mindset and an extensive network. He will focus on the development of
ingredient sales to brand owners and contract manufacturers for both pro- and
prebiotics in close cooperation with our established partners.

 

Shiraz has successfully developed the e-commerce businesses for a range of
companies, such as PhD (now part of Science In Sports) and Iovate Health
Sciences. He has built digital sales from the ground up into significant
contributors to the success of the companies he has worked for. Shiraz will
focus on developing the untapped e-commerce potential of our pro- and
prebiotic brands such as SlimBiome Medical, Go-Figure and CholBiome.

 

Karl Burkitt has a rich career in which he developed and led the marketing and
business development function in various branded and ingredient businesses,
such as Novartis Consumer Health, Kerry Ingredients & Flavours and AB
Mauri. Karl will lead our marketing function, on a part time basis, and work
closely with the pro- and prebiotic commercial divisions on developing
ingredient and consumer sales.

 

The above appointments expand the capabilities of our management team in line
with our commercial strategy, which is to further expand ingredient sales,
particularly in the large North American market, whilst developing our final
product sales containing our unique ingredients.

 

René Kamminga, CEO of OptiBiotix Ltd, commented: "In the past 12 months we
have established the credibility and brand awareness of our science-based
ingredients SlimBiome®, OptiBiome, LeanBiome and LP(LDL)® ingredients,
significantly growing sales to a wider number of reputable global brands in
multiple markets. These appointments are a further investment to accelerate
the growth of the Company and to broaden and deepen our income streams with a
particular focus on North America and E-Commerce."

 

(1)These appointments are non-statutory director appointments in the Company
or its subsidiaries.

 

For further information, please contact:

 

 OptiBiotix Health plc                                  www.optibiotix.com (http://www.optibiotix.com/)
 Stephen O'Hara, Chief Executive  Contact via Walbrook below

 Cenkos Securities plc (Broker)                         Tel: 020 7397 8900
 Callum Davidson / Neil McDonald
 Michael Johnson / Russell Kerr (Sales)

 Walbrook PR Ltd                                        Mob: 07407 804 654
 Alice Woodings

 

This communication is a "Reach" announcement. Reach is a non-regulatory news
service. By using this service an issuer is confirming that the information
contained in this announcement is of a non-regulatory nature. Information
required to be notified under the AIM Rules for Companies, Market Abuse
Regulation or other regulation would be disseminated as an RNS regulatory
announcement and not on RNS Reach.

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRATPMRTMTJTBAT